NCT03602612 2026-02-25
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
Clinical Trials
74 trialsNCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
NCT03702725 2026-01-06
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Phase 1 Completed
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT02675452 2025-07-09
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Amgen
Phase 1 Terminated
NCT05121103 2025-06-22
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Ipsen
Phase 1 Terminated
NCT03770260 2025-06-19
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
National Cancer Institute (NCI)
Phase 1 Completed
NCT03994705 2025-05-15
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Cartesian Therapeutics
Phase 1 Terminated
NCT04177823 2025-03-20
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 1 Completed
NCT03269136 2025-03-18
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
Pfizer
Phase 1 Completed
NCT03582033 2024-12-24
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Seagen Inc.
Phase 1 Terminated
NCT02043847 2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1 Completed
NCT04798586 2024-09-27
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
Pfizer
Phase 1 Completed
NCT02099539 2024-09-26
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Altor BioScience
Phase 1 Terminated
NCT02939183 2024-09-26
INTREPID-1
Amgen
Phase 1 Completed
NCT02148913 2024-07-26
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Corewell Health West
Phase 1 Completed
NCT04434469 2024-07-03
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Completed
NCT02663518 2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Phase 1 Terminated
NCT01995708 2024-02-09
CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02561962 2024-02-01
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
Amgen
Phase 1 Completed
NCT03318861 2023-10-19
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
Phase 1 Terminated
NCT03338972 2023-09-08
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT03465540 2023-04-12
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Amgen
Phase 1 Terminated
NCT04075721 2023-03-24
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone
EMD Serono
Phase 1 Terminated
NCT01607892 2023-01-26
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Karyopharm Therapeutics Inc
Phase 1 Completed
NCT01380145 2022-10-25
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02716805 2022-10-12
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT02514239 2022-02-24
Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients
Boehringer Ingelheim
Phase 1 Completed
NCT03168438 2022-01-11
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
GlaxoSmithKline
Phase 1 Terminated
NCT03018223 2021-09-16
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03958656 2021-09-09
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02481934 2021-08-20
NK-VS-MM
Hospital Universitario 12 de Octubre
Phase 1 Completed
NCT01953692 2021-08-04
MK-3475-013
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01999335 2021-04-27
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
Amgen
Phase 1 Terminated
NCT00858234 2021-04-09
MK-0683-098
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02036502 2021-04-08
MK-3475-023
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01713582 2021-01-26
MK-8628-001
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Completed
NCT00642954 2020-11-18
MK-0683-074
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02335983 2020-11-06
Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Amgen
Phase 1 Completed
NCT02100657 2020-10-12
Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
PharmaMar
Phase 1 Completed
NCT02064387 2020-08-11
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
GlaxoSmithKline
Phase 1 Completed
NCT02211014 2020-07-31
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
Acerta Pharma BV
Phase 1 Completed
NCT02492750 2020-03-25
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT01587703 2020-03-16
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
GlaxoSmithKline
Phase 1 Completed
NCT02082977 2020-02-25
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
GlaxoSmithKline
Phase 1 Terminated
NCT00652626 2019-11-19
RENAL
Celgene
Phase 1 Completed
NCT02043860 2019-10-14
BMT-02
University of Illinois at Chicago
Phase 1 Terminated
NCT02215967 2019-10-08
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00687674 2019-08-20
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Terminated